Dr. Duliege, is the Senior Executive and Chief Medical Officer for PanCAN where she is responsible for the organization’s clinical initiatives, including the Precision Promise℠ clinical trial. She has extensive experience in the biopharmaceutical industry; most recently, she was EVP and CMO at Rigel Pharmaceuticals. Previously, she was an epidemiologist with the National Institute of Science and Medical Research in Paris. Dr. Duliege received her M.D. degree and certification in Pediatrics from Paris Medical School, an M.S. in Epidemiology from Harvard School of Public Health, and an M.S. in Biostatistics also from Paris Medical School. She continues to practice medicine as an Adjunct Clinical Assistant Professor at Stanford School of Medicine and Lucile Packard Children’s Hospital. In 2012, she was appointed by the California State Controller to serve on the board of CIRM, the California Institute for Regenerative Medicine (stem cell research). She also serves on the board of Fe Pharmaceuticals and the boards of nonprofit organizations focused on causes such as the prevention of HIV or improving access to health care in developing countries.